PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection

PURPOSE OF REVIEW: Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this review, we critically summarize our knowledge on emerging cholesterol-lowering therapy, targeting PCSK9, paying particular attenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Natalie, Koenig, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Lipid Abnormalities and Cardiovascular Prevention (ED Michos, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729136/
https://www.ncbi.nlm.nih.gov/pubmed/36087240
http://dx.doi.org/10.1007/s11886-022-01782-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729136/
https://www.ncbi.nlm.nih.gov/pubmed/36087240
http://dx.doi.org/10.1007/s11886-022-01782-6

Ejemplares similares